847 related articles for article (PubMed ID: 29237833)
21. Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States.
Johnson J; Zhai Y; Salimi H; Espy N; Eichelberger N; DeLeon O; O'Malley Y; Courter J; Smith AB; Madani N; Sodroski J; Haim H
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490588
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/B' env molecular clones derived from infections in China.
Xie H; Nie J; Chen Q; Huang W; Wang Y
Emerg Microbes Infect; 2018 May; 7(1):90. PubMed ID: 29769530
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
[TBL] [Abstract][Full Text] [Related]
24. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
[TBL] [Abstract][Full Text] [Related]
25. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.
Landais E; Huang X; Havenar-Daughton C; Murrell B; Price MA; Wickramasinghe L; Ramos A; Bian CB; Simek M; Allen S; Karita E; Kilembe W; Lakhi S; Inambao M; Kamali A; Sanders EJ; Anzala O; Edward V; Bekker LG; Tang J; Gilmour J; Kosakovsky-Pond SL; Phung P; Wrin T; Crotty S; Godzik A; Poignard P
PLoS Pathog; 2016 Jan; 12(1):e1005369. PubMed ID: 26766578
[TBL] [Abstract][Full Text] [Related]
26. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
Wagh K; Seaman MS; Zingg M; Fitzsimons T; Barouch DH; Burton DR; Connors M; Ho DD; Mascola JR; Nussenzweig MC; Ravetch J; Gautam R; Martin MA; Montefiori DC; Korber B
PLoS Pathog; 2018 Mar; 14(3):e1006860. PubMed ID: 29505593
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
[TBL] [Abstract][Full Text] [Related]
28. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK
Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328
[TBL] [Abstract][Full Text] [Related]
29. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.
Anthony C; York T; Bekker V; Matten D; Selhorst P; Ferreria RC; Garrett NJ; Karim SSA; Morris L; Wood NT; Moore PL; Williamson C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28679760
[TBL] [Abstract][Full Text] [Related]
30. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
31. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.
Wagh K; Bhattacharya T; Williamson C; Robles A; Bayne M; Garrity J; Rist M; Rademeyer C; Yoon H; Lapedes A; Gao H; Greene K; Louder MK; Kong R; Karim SA; Burton DR; Barouch DH; Nussenzweig MC; Mascola JR; Morris L; Montefiori DC; Korber B; Seaman MS
PLoS Pathog; 2016 Mar; 12(3):e1005520. PubMed ID: 27028935
[TBL] [Abstract][Full Text] [Related]
32. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.
Andrabi R; Voss JE; Liang CH; Briney B; McCoy LE; Wu CY; Wong CH; Poignard P; Burton DR
Immunity; 2015 Nov; 43(5):959-73. PubMed ID: 26588781
[TBL] [Abstract][Full Text] [Related]
33. The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.
Provine NM; Cortez V; Chohan V; Overbaugh J
Virology; 2012 May; 427(1):25-33. PubMed ID: 22369748
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms.
Deshpande S; Patil S; Kumar R; Hermanus T; Murugavel KG; Srikrishnan AK; Solomon S; Morris L; Bhattacharya J
Retrovirology; 2016 Aug; 13(1):60. PubMed ID: 27576440
[TBL] [Abstract][Full Text] [Related]
35. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
36. Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.
Steinhardt JJ; Guenaga J; Turner HL; McKee K; Louder MK; O'Dell S; Chiang CI; Lei L; Galkin A; Andrianov AK; A Doria-Rose N; Bailer RT; Ward AB; Mascola JR; Li Y
Nat Commun; 2018 Feb; 9(1):877. PubMed ID: 29491415
[TBL] [Abstract][Full Text] [Related]
37. Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.
Reh L; Magnus C; Kadelka C; Kühnert D; Uhr T; Weber J; Morris L; Moore PL; Trkola A
PLoS Pathog; 2018 Jan; 14(1):e1006825. PubMed ID: 29370298
[TBL] [Abstract][Full Text] [Related]
38. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
Zhang Z; Li S; Gu Y; Xia N
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
[TBL] [Abstract][Full Text] [Related]
39. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.
Hraber P; Korber BT; Lapedes AS; Bailer RT; Seaman MS; Gao H; Greene KM; McCutchan F; Williamson C; Kim JH; Tovanabutra S; Hahn BH; Swanstrom R; Thomson MM; Gao F; Harris L; Giorgi E; Hengartner N; Bhattacharya T; Mascola JR; Montefiori DC
J Virol; 2014 Nov; 88(21):12623-43. PubMed ID: 25142591
[TBL] [Abstract][Full Text] [Related]
40. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
